Thursday, 02. December 2010

Nebulised antibiotic: decreased exacerbations and better quality of life for patients with bronchiectasis

The largest long-term study on an inhaled antibiotic to date demonstrated that the therapy helps patients in multiple ways

The 65 study participants benefited from significantly less exacerbations and related hospital stays, a reduced bacterial colonisation of the lung, and improved stress tolerance resulting in increased quality of life.

The study was carried out in Great Britain where 65 patients with bronchiectasis were treated for a period of 12 months with an antibiotic (gentamicin) or a matched placebo, administered twice daily with a jet nebulizer. Lung function, quality of life, bacterial density in sputum as well as the number of acute exacerbations were monitored at baseline and then every three months. Therapy with nebulized gentamicin proved significantly superior to placebo treatment for all parameters except lung function. This therapeutic option offers a distinct benefit especially for the prevention of acute exacerbations and for subjective well-being.

This study highlights an important aspect that nebulized antibiotic therapy should be considered as long-term treatment. Otherwise, the clinical picture may deteriorate quite rapidly after withdrawal of therapy. This course was evident three months after treatment when all parameters approached the values found before study initiation.


Diagramm - Murray 2010

Patients on nebulised gentamcin had less flare ups

 Diagramm - Murray 2010

Quality of life significantly improved with treatment of inhaled gentamicin

Source: Murray et al. (2010) Am J Respir Crit Care Med: epub ahead of print